XOMA Corporation-Product Pipeline Review-2015

XOMA Corporation-Product Pipeline Review-2015

  • Products Id :- GMDHC07177CDB
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

XOMA Corporation-Product Pipeline Review-2015


Global Markets Direct's, 'XOMA Corporation-Product Pipeline Review-2015', provides an overview of the XOMA Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of XOMA Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of XOMA Corporation including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of XOMA Corporation's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the XOMA Corporation's pipeline products

Reasons To Buy

Evaluate XOMA Corporation's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of XOMA Corporation in its therapy areas of focus

Identify new drug targets and therapeutic classes in the XOMA Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of XOMA Corporation and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of XOMA Corporation

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of XOMA Corporation and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

XOMA Corporation Snapshot 5

XOMA Corporation Overview 5

Key Information 5

Key Facts 5

XOMA Corporation-Research and Development Overview 6

Key Therapeutic Areas 6

XOMA Corporation-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Out-Licensed Products 11

Out-Licensed Products/Combination Treatment Modalities 12

XOMA Corporation-Pipeline Products Glance 13

XOMA Corporation-Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

XOMA Corporation-Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

XOMA Corporation-Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

XOMA Corporation-Drug Profiles 18

gevokizumab 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

XOMA-3-AB 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

XOMA-358 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Monoclonal Antibodies for Undisclosed Disease 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

XMet-A 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

XMet-S 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Antibodies to Antagonize RON for Oncology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Antibody to Modulate GPCR 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

XOMA Corporation-Pipeline Analysis 28

XOMA Corporation-Pipeline Products by Target 28

XOMA Corporation-Pipeline Products by Route of Administration 29

XOMA Corporation-Pipeline Products by Molecule Type 30

XOMA Corporation-Pipeline Products by Mechanism of Action 31

XOMA Corporation-Recent Pipeline Updates 32

XOMA Corporation-Dormant Projects 38

XOMA Corporation-Discontinued Pipeline Products 39

Discontinued Pipeline Product Profiles 39

efalizumab 39

gevokizumab 39

XOMA Corporation-Company Statement 40

XOMA Corporation-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

XOMA Corporation, Key Information 5

XOMA Corporation, Key Facts 5

XOMA Corporation-Pipeline by Indication, 2015 7

XOMA Corporation-Pipeline by Stage of Development, 2015 9

XOMA Corporation-Monotherapy Products in Pipeline, 2015 10

XOMA Corporation-Out-Licensed Products in Pipeline, 2015 11

XOMA Corporation-Out-Licensed Products/ Combination Treatment Modalities, 2015 12

XOMA Corporation-Phase III, 2015 13

XOMA Corporation-Phase II, 2015 14

XOMA Corporation-Phase I, 2015 15

XOMA Corporation-Preclinical, 2015 16

XOMA Corporation-Discovery, 2015 17

XOMA Corporation-Pipeline by Target, 2015 28

XOMA Corporation-Pipeline by Route of Administration, 2015 29

XOMA Corporation-Pipeline by Molecule Type, 2015 30

XOMA Corporation-Pipeline Products by Mechanism of Action, 2015 31

XOMA Corporation-Recent Pipeline Updates, 2015 32

XOMA Corporation-Dormant Developmental Projects,2015 38

XOMA Corporation-Discontinued Pipeline Products, 2015 39

XOMA Corporation, Subsidiaries 42

List of Figures

XOMA Corporation-Pipeline by Top 10 Indication, 2015 7

XOMA Corporation-Pipeline by Stage of Development, 2015 9

XOMA Corporation-Monotherapy Products in Pipeline, 2015 10

XOMA Corporation-Out-Licensed Products in Pipeline, 2015 11

XOMA Corporation-Pipeline by Top 10 Target, 2015 28

XOMA Corporation-Pipeline by Top 10 Route of Administration, 2015 29

XOMA Corporation-Pipeline by Top 10 Molecule Type, 2015 30

XOMA Corporation-Pipeline Products by Top 10 Mechanism of Action, 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of XOMA Corporation; XOMA Corporation - Key Therapeutics; XOMA Corporation - Pipeline Overview and Promising Molecules; XOMA Corporation - News; XOMA Corporation - Latest Updates; XOMA Corporation - Pipeline; XOMA Corporation - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101595
Site License
USD 3000 INR 203190
Corporate User License
USD 4500 INR 304785



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com